A Systematic Review and Meta-Analysis on the Efficacy of Puerarin Injection as Adjunctive Therapy for Unstable Angina Pectoris

Huikai Shao1,2†, Yang Huang3†, Dongsheng Xu4*, Shengfeng Huang3* and Rongsheng Tong1,2*

1 Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China, 2 Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, 3 Key Laboratory of Molecular Target & Clinical Pharmacology and the State & NMPA Key Laboratory, School of Pharmaceutical Sciences & the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, 4 Institute of Pharmaceutical Analysis, College of Pharmacy, Jinan University, Guangzhou, China

Background: As adjunctive therapy, puerarin injection has been widely applied for the treatment of unstable angina pectoris (UAP) in China during the past decades. However, the efficacy of puerarin injection as adjunctive therapy for UAP has not been well confirmed. The purpose of this meta-analysis was to summarize the available evidence to estimate the efficacy of puerarin injection in treating UAP.

Objective: A systematic review and meta-analysis with subgroup analysis and sensitivity analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) principle were carried out to evaluate the efficacy of puerarin injection as adjunctive therapy in treating UAP.

Methods: To obtain the published randomized controlled trials (RCTs) on puerarin injection, databases, namely, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database, Sino-Med, PubMed, China Science and Technology Journal Database (VIP), Medline, Google Scholar, Cochrane Library, Chinese Science Citation Database, and Embase were systematically searched until June 2021. In this meta-analysis, Review Manager version 5.3 software and Stata version 12.0 software were employed to analyze the collected data. Based on the methodological quality, years of publications, sample size and dosages, sensitivity analysis, and subgroup analysis were performed. The GRADE assessment was conducted by the software GRADEpro version 3.6 software.

Results: A total of 17 RCTs involving 1,459 patients were included in this meta-analysis. Results indicated that puerarin injection as adjunctive therapy was more superior than conventional Western medicine alone in reducing angina symptoms [risk ratio (RR) = 1.22, 95% CI 1.16 to 1.28, Z = 8.11, p < 0.00001] and improving ECG (RR = 1.32, 95% CI 1.20 to 1.44, Z = 6.00, p < 0.00001), meanwhile reducing the frequency of angina attack [mean difference (MD) = −2.22, 95% CI −2.53 to −1.90, Z = 13.97, p < 0.00001] and the duration of angina attack (MD = −2.00, 95% CI −2.39 to −1.61,
INTRODUCTION

As a symptom of coronary artery disease (CAD), unstable angina pectoris (UAP) is characterized by clinical symptoms of left anterior chest pain or discomfort of adjacent areas. UAP is triggered by increased myocardial oxygen demand or decreased myocardial oxygen supply (1, 2). UAP can increase the risk of severe cardiac arrhythmias and acute myocardial infarction, which leads to sudden death (3). Owing to the complexity of UAP, lifelong medication is usually necessary for the patients. Therefore, appropriate treatment should be given to the patients timely after being diagnosed with UAP. Although conventional Western medicines, namely, β-blockers, calcium antagonists, and nitrates have been successfully used in decreasing anginal attacks, drug resistances, and adverse reactions were accompanied with these Western medicines (4, 5). Therefore, exploring a novel treatment method is of great importance for treating UAP. As an adjunctive therapy, traditional Chinese medicine (TCM) has attracted great interest due to its remarkable effectiveness, high bioavailability, and swift action (6). TCM as an adjunctive therapy could be a promising candidate to offer better therapeutic effects and avoid the adverse reactions caused by conventional Western medicines (6).

Puerarin (Supplementary Figure 1) injection, a natural isoflavone, was isolated from Pueraria lobata root (7). The concentration of commercial puerarin injection was determined as 50 mg/ml and it was usually given to the patients by intravenous drip (diluted with 250 ml of 5% glucose injection, once per day). A large number of studies have demonstrated that puerarin injection was beneficial for the cardiovascular system by expanding the coronary artery to relieve vasospasm and increasing coronary blood flow, thus improving the blood supply to ischemic myocardium (8). Puerarin injection also can be used to decrease blood pressure, heart rate, and myocardial oxygen consumption (9). Moreover, this injection plays important role in inhibiting platelet aggregation, decreasing blood viscosity, and improving microcirculation (10). To provide great efficacy, puerarin injection was usually integrated with Western medicines (nitroglycerin, isosorbide nitrate, nifedipine, aspirin, trimetazidine, metoprolol, etc.) for the treatment of UAP in China.

To date, lots of randomized controlled trials (RCTs) reported positive results on the therapeutic effect of puerarin injection for UAP. However, the efficacy of puerarin injection as an adjunctive therapy for UAP has not been well evaluated. Hence, the study aimed to conduct a comprehensive and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-compliant systematic review with sensitivity and subgroup analysis to validate the efficacy of puerarin injection as an adjunctive therapy in treating UAP (2, 11–14).

METHODS

Eligibility Criteria

Two authors (Shao HK and Huang Y) independently screened the eligible RCTs based on the inclusion criteria as follows: (1) RCTs investigating the therapeutic effect and safety on puerarin injection as an adjunctive therapy (puerarin injection combined with Western medicines vs. Western medicines alone) in the treatment of UAP were included in this meta-analysis; (2) The diagnosis of UAP was based on “the 2002 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the diagnosis and management of patients with unstable ischemic heart disease (2002 ACC/AHA)” (15) or “the WHO guideline” (1) or “the diagnostic criteria of UAP developed by the Chinese Society of Cardiology” (16). (3) Duration of the treatment was more than 10 days; (4) the numbers of patients with UAP were more than 40; and (5) symptomatic improvement, ECG improvement, frequency of angina attack (time/week), or duration of angina attacks were defined as the outcome measures.

Randomized controlled trials should be excluded, if they did not meet with the above criteria: (a) Formulation and dosages of intervention in the control and treatment groups were not provided in detail; (b) Incomplete data or duplication existed; (c) Another TCM was used; and (d) Animal or tissue cell was involved.

Information Sources

To obtain the RCTs about the adjunctive therapy of puerarin injection for UAP, databases involving China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database, Google Scholar, Wanfang Database, Sino-Med, China Science and Technology Journal Database (VIP), PubMed, Medline, Cochrane Library, Embase, and Chinese Science Citation Database were systematically searched and screened. The latest search was carried out on June 28, 2021.

Search Strategies

In English databases, the following keywords were searched in separate or joint methods: puerarin, puerarin injection, unstable angina pectoris, and angina pectoris. In Chinese databases,
the following keywords were searched in separate or joint methods: Gegensu (puerarin), Gegensu Zhushey (puerarin injection), Buwending Xinjiaotong (unstable angina pectoris), and Xinjiaotong (angina pectoris). Besides, the references in the included RCTs were also screened to obtain the eligible RCTs.

**Study Selection**
Two authors (Shao HK and Huang Y) independently searched the databases to obtain the eligible RCTs according to the inclusion and exclusion criteria. Disagreements between these two authors during the process of study selection were resolved by discussion.

**Data Collection Process**
One author (Shao HK) read the full text of the eligible RCTs and collected data. Another author (Huang Y) checked the accuracy and completeness of the collected data. Disagreement during this process was resolved through discussion with a third author (Xu DS). Review Manager version 5.3 software (Cochrane Collaboration, Nordic Cochrane Centre, Copenhagen, Denmark) and Stata version 12.0 software (Stata Corp LLC, College Station, Texas, USA) were adopted to analyze the collected data.

**Data Items**
In the included RCTs, the following items were collected: (1) First author; (2) Publication date; (2) Sample size of patients; (3) Interventions (including the dosages and duration) in the control group and the treatment control group; (4) Outcome measures; and (5) Adverse reactions.

**Quality Assessment**
Two authors (Shao HK and Huang Y) independently evaluated the methodological quality of the included RCTs with the Jadad scale (Supplementary Table 1) and its refined revision M scale (2, 12, 13, 17). In the Jadad score, the methodological quality of the included RCTs was evaluated based on the items of randomization, blinding, and withdrawals (dropouts). The range of the Jadad score was from 0 (poorest) to 5 (highest). Scores were given to the RCTs if: randomization was described, 1 score; appropriate randomization, 1 score; double-blinding was described, 1 score; appropriate double-blinding, 1 score; withdrawals or dropouts were described, 1 score. RCTs obtained 3 to 5 scores were regarded as high quality, while RCTs obtained 1 or 2 scores were regarded as low quality. Two authors (Shao HK and Huang Y) independently evaluated the methodological quality of the included RCTs using the Jadad scale and M scale (RCTs with M score above 3 were regarded as high quality). Any disagreement during this process between these two authors was resolved through discussion with a third author (Xu DS).

**Sensitivity and Subgroup Analysis**
Sensitivity analysis was conducted to evaluate whether the overall therapeutic effect of puerarin injection as adjunctive therapy for UAP was impacted by the low-quality RCTs. Subgroup analysis was conducted to evaluate whether the overall therapeutic effects were homogeneous in subgroups according to sample size, publication date, and dosages of puerarin injection.

**Risk of Bias Across Studies**
The funnel plot created by the software STATA version 12.0 was employed to evaluate the potential publication bias. Begg’s test and Egger's test were also used to detect the potential publication bias in this meta-analysis.

**Statistical Analysis**
RevMan version 5.3 was used for the statistical analysis. The dichotomous variable was represented as the pooled risk ratios (RRs) with 95%CI. The continuous variable was represented as the weighted mean difference (MD) with 95%CI. I² statistic and the chi-squared test were employed to evaluate the heterogeneity between the included RCTs. If I² > 50% or p < 0.05, it suggested that a significant statistical heterogeneity was observed and the random-effect model should be employed to evaluate the outcome measures. Otherwise, the fixed-effect model was adopted. To evaluate whether the overall effects of puerarin injection as adjunctive therapy were superior to Western medicine alone for UAP, Z-test was employed. If p < 0.05, it suggested that there was a significant statistical difference in this meta-analysis.

**Evidence Quality Assessment**
The evidence quality assessment was independently conducted by two authors (Shao HK and Huang Y) based on the GRADE criteria (18). The evidence quality of the included outcomes was defined as high, moderate, low, and very low. The evidence of RCTs was initially considered as high-quality. The quality of each outcome was downgraded according to the following five factors: risk of bias, inconsistency, indirectness, imprecision, and publication bias. In this study, GRADEpro version 3.6.1 software was adopted for the data analysis and synthesis.

**RESULTS**

**Study Selection**
The process of study selection for the eligible RCTs is shown in Figure 1. A total of 3,490 potential studies were initially identified from the databases according to the search strategies. A total of 2902 studies were excluded because they were reviews or duplication. Full texts of 105 studies were retrieved for manually screening according to the eligibility criteria. Finally, 17 RCTs were included for further quality evaluation and meta-analysis.

**Study Characteristics**
The detailed characteristics of the included 17 RCTs are given in Table 1. All the 17 RCTs were reported in Chinese language journals and the publication date was from 2000 to 2017 (19–35). The number of patients with UAP in the included RCTs ranged from 40 to 168 and the mean sample size was 85.8. The duration of the treatment was ranging from 10 to 14 days. Western medicines used in the control group included isosorbide dinitrate, nifedipine, aspirin, nitroglycerin, caltrate with vitamin D tablet, alendronate sodium tablet, metoprolol, atorvastatin calcium tablet, trimetazidine tablet, diltiazem hydrochloride tablets, coenzyme, clopidogrel, fluvastatin, isosorbide mononitrate, and low-molecular-weight
heparin calcium. Combined with these Western medicines, the dosage of puerarin injection in the treatment group ranged from 60 to 500 mg per day. The symptomatic change was selected as the outcome measure in 17 RCTs. ECG was reported as the outcome measure in eight RCTs.

Risk of Bias in Individual Studies
To evaluate the quality of the included 17 RCTs, the Jadad scale (ranged from 0 to 5 scores) and M scale (ranged from −1 to 7 scores) were employed. As shown in Table 2, according to the Jadad scale, 3 RCTs were given 3 scores.
| References          | Intervention                                                                 | Sample size | Course of treatment (day) | Outcome measures |
|---------------------|------------------------------------------------------------------------------|-------------|---------------------------|------------------|
| Cai and Liu (19)    | Puerarin injection 60 mg, isosorbide nitrate 10 mg, nifedipine 15–30 mg, asprin 50 mg, nitroglycerin 0.3–0.6 mg | 40          | 20                        | Symptoms         |
| Chen and Yan (20)   | Puerarin injection 200 mg, caltrate with vitamin D tablet 600 mg, alendronate sodium tablet 70 mg, nitroglycerin 1.5 mg, Metoprolol 150 mg, atorvastatin calcium tablet 20 mg, trimetazidine tablet 60 mg | 54          | 14                        | Symptoms         |
| Chen and Yan (20)   |                                    | 53          | 14                        | Symptoms         |
| Fan and Lv (21)     | Puerarin injection 500 mg, asprin 100 mg, isosorbide dinitrate 15 mg        | 39          | 15                        | Symptoms ECG     |
| Guo et al. (22)     | Puerarin injection 400 mg, nitroglycerin injection 5 mg                      | 36          | 14                        | Symptoms         |
| Huang et al. (23)   | Puerarin injection 500 mg, asprin 100 mg, isosorbide dinitrate 30 mg, nitroglycerin 10 mg | 30          | 14                        | Symptoms ECG     |
| Li and Ji (25)      | Puerarin injection 400 mg, isosorbide dinitrate 30 mg, metoprolol 50–100 mg, asprin 100 mg | 58          | 15                        | Symptoms ECG     |
| Liu (26)            | Puerarin injection 500 mg, isosorbide dinitrate 30 mg, diltiazem hydrochloride tablets 90 mg, metoprolol 25 mg, asprin 100 mg | 34          | 10                        | Symptoms ECG     |
| Meng (27)           | Puerarin injection 400 mg, isosorbide dinitrate 30 mg, asprin 100 mg, clopidogrel 75 mg, nitroglycerin 10 mg | 30          | 14                        | Symptoms ECG     |
| Wang and Jiang (28) | Puerarin injection 400 mg, isosorbide dinitrate 10 mg, asprin 50–100 mg, nifedipine 10 mg, nitroglycerin 0.6 mg | 29          | 10                        | Symptoms         |
| Xia et al. (29)     | Puerarin injection 500 mg, clopidogrel 75 mg                               | 57          | 28                        | Symptoms         |

(Continued)
(high quality) and the rest of 14 RCTs were given 2 scores (low quality). According to the M scale, 10 RCTs were given 3 scores (low quality) and 7 RCTs were given 4 scores (high quality).

**Angina Symptoms**

Angina symptoms were selected as the outcome measure in 17 RCTs. As shown in Figure 2, results from this meta-analysis showed that the pooled RR was 1.22 (95% CI 1.16 to 1.28; Z = 8.11, p < 0.00001) among the 17 RCTs, which suggested that using puerarin injection as adjunctive therapy was more effective than using Western medicine alone in treating UAP. Due to the low heterogeneity (p = 0.77, I² = 0%), the fixed-effect model was employed in this meta-analysis. As shown in Figure 3, the potential publication bias among the 17 RCTs was assessed by funnel plots and results suggested that slight asymmetry was observed. Results from Begg’s test (Z = 3.75, p = 0) and Egger’s test (t = 7.25, p = 0) also indicated that there was publication bias. To evaluate whether the overall effect of puerarin injection as adjunctive therapy superior to Western medicine alone in treating UAP would be affected by the low-quality RCTs, a sensitivity analysis was conducted. As shown in Table 3, no obvious difference was observed when low-quality RCTs were gradually excluded according to the M scale. Slight changes (0.02 in magnitude) were observed between the high-quality (M scale > 3) and low-quality (M scale ≤ 3) RCTs. To evaluate whether the overall effect was affected by sample size, publication date, and dosages of puerarin injection among the included RCTs, subgroup analysis was conducted (Supplementary Table 2). No significant difference was observed in the pooled RRs, which consistently demonstrated that the therapeutic efficacy of puerarin injection as adjunctive therapy surpassed Western medicine alone in treating UAP.

**Electrocardiogram Improvement**

Electrocardiogram improvement was selected as the outcome measure in eight RCTs. The fixed-effect model was employed to analyze the collected data since there was no significant heterogeneity (p = 0.31, I² = 16%). As shown in Figure 4, the pooled RR was 1.32 (95% CI 1.20 to 1.44; Z = 6.00, p < 0.00001) among the eight RCTs, which indicated puerarin injection as
adjunctive therapy was more effective than Western medicine alone in the improvement for ECG. To evaluate whether the overall effect of puerarin injection as adjunctive therapy was more effective than Western medicine alone in ECG improvement were affected by low-quality RCTs, sensitivity analysis was conducted in this meta-analysis. As shown in Table 4, no significant difference was observed when low-quality RCTs were gradually excluded according to the M scale. Slight changes (0.05 in magnitude) were observed for the included RCTs with high quality (M scale > 3) and low quality (M scale ≤ 3). To evaluate whether the overall effect was affected by sample size, publication date, and dosages of puerarin injection among the eight RCTs, subgroup analysis was conducted (Supplementary Table 3). No significant difference was observed in the pooled RRs, which consistently demonstrated that puerarin injection as adjunctive therapy was better than Western medicine alone in treating UAP. The potential publication bias among the eight RCTs was assessed by funnel plots, as shown in Figure 5, results suggested that slight
asymmetry was observed. Results from Begg’s test ($Z = 2.10, p = 0.035$) and Egger’s test ($t = 3.72, p = 0.010$) also indicated that there was publication bias.

**Frequency of Angina Attack**

Three included RCTs reported the frequency of angina attacks (time/week). The random-effect model was used to analyze the data since there was significant heterogeneity ($I^2 = 77\%$, $p = 0.01$). As shown in **Figure 6**, results suggested that the adjunctive use of puerarin injection was better than Western medicine alone in reducing the frequency of angina attacks ($MD = −2.58; 95\% CI −3.35 to −1.81; Z = 6.55, p < 0.00001$). To evaluate if the overall effect in reducing the frequency of angina attack was influenced by low-quality RCTs, sensitivity analysis was performed. As shown in **Table 5**, there was a significant difference when the low-quality RCTs were gradually excluded based on the M scale. Big changes (2.46 in magnitude) were found for the included RCTs with high quality (M scale $> 3$) and low quality (M scale $\leq 3$). To assess if the overall effect was influenced by sample size and publication date among the three RCTs, subgroup analysis was introduced in this meta-analysis (**Supplementary Table 4**). A significant difference was observed in the overall MDs. After carefully reading the original RCT (23), it was found that the 26 patients with initial onset angina pectoris could be the important reason leading to heterogeneity. Hence, we removed this RCT and pooled other two RCTs alone ($MD = −2.22, 95\% CI −2.53 to −1.90, Z = 13.97, I^2 = 0\%, p < 0.00001$).

**Duration of Angina Attack**

Duration of angina attacks (minutes for each attack) was reported in three included RCTs in this meta-analysis. There was significant heterogeneity ($I^2 = 87\%, p = 0.0004$) and random effect model was adopted. As shown in **Figure 7**, results indicated that puerarin injection as adjunctive therapy had a better therapeutical effect in reducing the duration of angina attacks than Western medicine alone ($MD = −2.56, 95\% CI −3.45 to −1.66, Z = 5.62, p < 0.00001$). To evaluate if the overall effect of MDs in reducing the duration of angina attack was influenced by low-quality RCTs, sensitivity analysis was performed. As shown in **Table 6**, a significant difference was observed when the low-quality RCTs were gradually excluded. Significant changes (2.67 in magnitude) were found for the included three RCTs with high quality (M scale $> 3$) and low quality (M scale $\leq 3$). To assess if the overall effect of MDs was influenced by sample size and publication date among the three RCTs, subgroup analysis was introduced in this meta-analysis (**Supplementary Table 5**). A significant difference was observed in the overall MDs. For the same reason, the heterogeneity was attributed to the patients with initial onset angina pectoris in the RCT (23). Finally, this RCT was removed and other two RCTs were pooled alone ($MD = −2.00, 95\% CI −2.39 to −1.61, Z = 9.99, I^2 = 50\%, p < 0.00001$).

**Adverse Reaction**

Six included RCTs reported adverse reactions and one study described that no adverse reaction happened during the treatment. The rest of the studies did not report adverse reactions. As shown in **Table 7**, puerarin injection as adjunctive therapy could cause headache (3 cases), fever (5 cases), abdominal distension (4 cases), pruritus (3 cases), nausea (1 case), orthostatic hypotension (1 case), dizzy (1 case), and perspiration (1 case). No adverse reaction was reported in the control group (Western medicine alone). Although the adjunctive use of puerarin injection could cause adverse reactions for the UAP patients, none of the reported adverse reactions were serious. Hence, puerarin injection was safe in treating UAP.

**GRADE Assessment**

The GRADE criteria were employed to evaluate the evidence quality for the two outcomes (symptom and ECG). Since only

---

**FIGURE 3** | Funnel plot of outcome measure symptoms.

**TABLE 3** | Sensitivity analysis based on the outcome measure symptoms.

| Group | No. of RCTs | No. of patients | RR  | 95\% CI | Z    | $p$ (effect) | $I^2$ | $\chi^2$ | $p$ (het) |
|-------|-------------|----------------|-----|---------|------|--------------|------|----------|-----------|
| M scale |             |                |     |         |      |              |      |          |           |
| 0–5   | 17          | 1,459          | 1.22| 1.16, 1.28 | 8.11| $<0.00001$ | 0%   | 11.55    | 0.77      |
| 1–5   | 17          | 1,459          | 1.22| 1.16, 1.28 | 8.11| $<0.00001$ | 0%   | 11.55    | 0.77      |
| 2–5   | 17          | 1,459          | 1.22| 1.16, 1.28 | 8.11| $<0.00001$ | 0%   | 11.55    | 0.77      |
| 3–5   | 17          | 1,459          | 1.22| 1.16, 1.28 | 8.11| $<0.00001$ | 0%   | 11.55    | 0.77      |
| 4–5   | 7           | 559            | 1.23| 1.14, 1.33 | 5.18| $<0.00001$ | 0%   | 3.26     | 0.78      |
| ≤ 3   | 10          | 900            | 1.21| 1.14, 1.29 | 6.25| $<0.00001$ | 0%   | 8.07     | 0.53      |
| > 3   | 7           | 559            | 1.23| 1.14, 1.33 | 5.18| $<0.00001$ | 0%   | 3.26     | 0.78      |
TABLE 4 | Sensitivity analysis based on the outcome measure ECG.

| Group | No. of RCTs | No. of patients | RR 95%CI | Z     | P (effect) | I² | χ² | P (het) |
|-------|-------------|-----------------|----------|-------|------------|----|-----|---------|
| M scale |             |                 |          |       |            |    |     |         |
| 0–5   | 8           | 660             | 1.32     | 1.20, 1.44 | 6.00 | <0.00001 | 16% | 8.30  | 0.31    |
| 1–5   | 8           | 660             | 1.32     | 1.20, 1.44 | 6.00 | <0.00001 | 16% | 8.30  | 0.31    |
| 2–5   | 8           | 660             | 1.32     | 1.20, 1.44 | 6.00 | <0.00001 | 16% | 8.30  | 0.31    |
| 3–5   | 8           | 660             | 1.32     | 1.20, 1.44 | 6.00 | <0.00001 | 16% | 8.30  | 0.31    |
| 4–5   | 4           | 282             | 1.29     | 1.13, 1.47 | 3.83 | 0.0001   | 16% | 3.58  | 0.31    |
| ≤ 3   | 4           | 378             | 1.34     | 1.18, 1.52 | 4.62 | <0.00001 | 31% | 4.33  | 0.23    |
| > 3   | 4           | 282             | 1.29     | 1.13, 1.47 | 3.83 | 0.0001   | 16% | 3.58  | 0.31    |

DISCUSSION

As a serious clinical syndrome subset of the acute coronary syndromes, UAP can easily deteriorate into sudden death (3). Conventional Western medicines, namely, calcium antagonists, β-blockers, and nitrates have been successfully employed to decrease anginal attacks. However, these medicines might have unsatisfied therapeutic effects for UAP due to their potential adverse reactions and drug resistances (4, 5). Puerarin injection as adjunctive therapy could be an effective way to provide better therapeutic effects for UAP since it can protect against myocardial ischemia/reperfusion injury by regulating the inflammatory response and NLRP3 inflammasome, which could be a good candidate to treat ischemic heart disease (36). So far, a large number of studies reported that the combined use of puerarin injection and conventional Western medicines presented positive therapeutic effects in treating UAP. However, the efficacy of puerarin injection for UAP has not been well verified at present. Recently, a meta-analysis and systematic review were performed for evaluating the clinical efficacy and safety of puerarin injection on the treatment of UAP (37). Although results from their study showed that puerarin injection in combination with conventional Western medicines exhibited significant improvements in the incidence of angina pectoris, electrocardiogram findings, nitroglycerin consumption, and plasma endothelin levels, several limitations still existed in their research. First, in this study, the meta-analysis and systematic review were not strictly designed according to the PRISMA statements. Second, the formulation and dosages of Western medicines in the control group were not described. Third, the detailed results of sensitivity analysis were lacking. Besides, subgroup analysis had not been conducted in their study. Fourth, only funnel plots were performed to evaluate the potential publication bias without Begg’s test and Egger’s test, which might cause inaccurate results. Hence, this study aimed to conduct a comprehensive and the PRISMA-compliant systematic review with sensitivity and subgroup analysis to evaluate the efficacy of puerarin injection as adjunctive therapy in treating UAP, providing a more reliable conclusion for puerarin injection.

Analysis of Effectiveness

After analysis of the RCTs on puerarin injection, the therapeutic efficacy of puerarin injection in treating UAP was proved to be effective. First, the combination use of UAP and Western medicines could improve the total effective rate of angina symptoms and ECG. In this meta-analysis, puerarin injection as adjunctive therapy displayed better therapeutic effects than...
Western medicine alone in reducing angina symptoms (RR 1.22, 95% CI 1.16 to 1.28, $Z = 8.11$, $p < 0.00001$) and improving ECG (RR 1.32, 95% CI 1.20 to 1.44, $Z = 6.00$, $p < 0.00001$), which indicated that puerarin injection as adjunctive therapy could provide better efficacy than Western medicine alone in treating UAP. This results met with the trends of the previous study (reduction in the number of angina pectoris attacks (RR 1.29, 95% CI 1.24 to −1.34, $Z = 13.07$, $p < 0.001$) and ECG improvement (RR 1.33, 95% CI 1.27 to 1.39, $Z = 12.30$, $p < 0.001$) (37)). Second, this study demonstrated that the adjunctive therapy of puerarin injection for UAP could reduce the frequency and duration of angina attack, which had not been evaluated in the previous study (37).

Third, in the study of Gao et al. (37), they found that the major adverse reactions included transient headache and fever, dizziness, hypotension, abdominal distention and nausea, allergic skin reactions, and sinus bradycardia. Moreover, all of the adverse reactions were mild, with spontaneous remission. In this study, several adverse reactions, namely, headache, fever, abdominal distension, pruritus, nausea, orthostatic hypotension, dizziness, and perspiration were observed. However, none of these adverse reactions were serious, which also consistently suggested that puerarin injection as adjunctive therapy was safe for the treatment of UAP. The good therapeutic efficacy of puerarin injection on UAP could be contributed to the numerous effects on the cardiovascular system. Previous studies have demonstrated that puerarin injection was beneficial for the cardiovascular system by expanding the coronary artery to relieve vasospasm and increasing coronary blood flow, thus improving the blood supply to the ischemic myocardium (8). Besides, it can decrease blood pressure, heart rate, and myocardial oxygen consumption (9). Puerarin injection also plays an important role in inhibiting platelet aggregation, decreasing blood viscosity, and improving microcirculation (10). The pharmacological effects of puerarin on the cardiovascular system have been summarized as follows: (1) Effects of antiarrhythmia: Antiarrhythmia effects of puerarin could be partly attributed to its influences on $Na^+$ and $K^+$ channels. Previous studies have demonstrated that puerarin could inhibit $K^+$ channels, which could prolong the duration of the action potential and the refractory period in cardiomyocytes to prevent arrhythmia development (38). Besides, puerarin could block $Na^+$ channels, which could significantly suppress the velocity of cardiac impulse conduction and prolong the refractory period of cardiac excitability, thus inhibiting the progression of arrhythmia (39). (2) Improving microcirculation: puerarin could improve myocardial microcirculation and cardiac

### Table 5: Sensitivity analysis based on the frequency of angina attacks.

| Group | No. of RCTs | No. of patients | MD    | 95% CI       | Z        | $p$ (effect) | $I^2$ | $\chi^2$ | $p$ (het) |
|-------|-------------|----------------|-------|--------------|----------|--------------|-------|----------|----------|
| M scale |             |                |       |              |          |              |       |          |          |
| 0–5   | 3           | 342            | −2.58 | −3.35, −1.81 | 6.55     | <0.00001     | 77%   | 8.76     | 0.01     |
| 1–5   | 3           | 342            | −2.58 | −3.35, −1.81 | 6.55     | <0.00001     | 77%   | 8.76     | 0.01     |
| 2–5   | 3           | 342            | −2.58 | −3.35, −1.81 | 6.55     | <0.00001     | 77%   | 8.76     | 0.01     |
| 3–5   | 3           | 342            | −2.58 | −3.35, −1.81 | 6.55     | <0.00001     | 77%   | 8.76     | 0.01     |
| 4–5   | 1           | 60             | −4.68 | −6.32, −3.04 | 5.59     | <0.00001     | /     | /        | /        |
| ≤ 3   | 2           | 282            | −2.22 | −2.53, −1.90 | 13.97    | <0.00001     | 0%    | 0.39     | 0.53     |
| > 3   | 1           | 60             | −4.68 | −6.32, −3.04 | 5.59     | <0.00001     | /     | /        | /        |
TABLE 6 | Sensitivity analysis based on the duration of angina attack.

| Group   | No. of RCTs | No. of patients | MD      | 95%CI    | Z     | P (effect) | I² | χ² | P (het) |
|---------|-------------|-----------------|---------|----------|-------|------------|----|-----|---------|
| M scale |             |                 |         |          |       |            |    |     |         |
| 0–5     | 3           | 342             | −2.56   | −3.45, −1.66 | 5.62 | <0.00001   | 87%| 15.45| 0.0004  |
| 1–5     | 3           | 342             | −2.56   | −3.45, −1.66 | 5.62 | <0.00001   | 87%| 15.45| 0.0004  |
| 2–5     | 3           | 342             | −2.56   | −3.45, −1.66 | 5.62 | <0.00001   | 87%| 15.45| 0.0004  |
| 3–5     | 3           | 342             | −2.56   | −3.45, −1.66 | 5.62 | <0.00001   | 87%| 15.45| 0.0004  |
| 4–5     | 1           | 60              | −4.67   | −6.07, −3.27 | 6.53 | <0.00001   | /  | /   | /       |
| ≤ 3     | 4           | 282             | −2.00   | −2.39, −1.61 | 9.99 | <0.00001   | 50%| 2.00 | 0.16    |
| > 3     | 1           | 60              | −4.67   | −6.07, −3.27 | 6.53 | <0.00001   | /  | /   | /       |

TABLE 7 | Incidence rate of adverse reaction.

| Type                | Number of adverse reactions | Treatment group | Control group | References |
|---------------------|----------------------------|-----------------|---------------|------------|
| Headache            | 3                          | 0               | (19, 22)      |
| Fever               | 5                          | 0               | (19, 21, 23)  |
| Abdominal distension| 4                          | 0               | (21)          |
| Pruritus            | 3                          | 0               | (21, 31)      |
| Nausea              | 1                          | 0               | (23)          |
| Orthostatic hypotension | 1                       | 0               | (31)          |
| Dizzy               | 1                          | 0               | (23)          |
| Perspiration        | 1                          | 0               | (25)          |

**Strengths and Limitations**

A large number of studies have reported that puerarin injection could improve the therapeutic efficacy of Western medicine in the treatment of UAP. However, the efficacy of puerarin injection as adjunctive therapy for UAP had not been verified. This study aimed to provide the PRISMA-compliant systematic review and meta-analysis to assess the efficacy of puerarin injection as adjunctive therapy in treating UAP (Supplementary Table 6). Although the benefits of puerarin injection for UAP have been proved by this meta-analysis, several limitations still existed. First, the methodological quality of several RCTs is low (only three RCTs scored 3 scores with the Jadad scale). Randomization is considered to be an effective way to avoid selection bias, while only three RCTs described the appropriate randomization method. Moreover, blinding for researchers or patients was not mentioned in all RCTs. These shortcomings could cause an overestimation or underestimation result for the adjunctive therapy in treating UAP. Second, the sample size of some RCTs was relatively small and the duration of treatment was relatively short, which might cause an inaccurate result for this meta-analysis. Therefore, more strictly designed RCTs with higher quality, larger sample size, and longer duration are urgent to be recommended to evaluate the efficacy of puerarin injection as adjunctive therapy for UAP. Third, the result from the GRADE system for the outcomes symptom and ECG indicated that the quality of evidence was low. More high-quality RCTs were recommended to verify the efficacy of puerarin injection as adjunctive therapy for UAP.
Implications for Further Research
Although the efficacy of puerarin injection as adjunctive therapy for UAP has been verified in this meta-analysis, the evidence was still insufficient due to the low-quality RCTs. Hence, several suggestions were recommended to conduct the studies on puerarin injection. First, studies on puerarin injection should be strictly designed according to the Consolidated Standards of Reporting Trials (CONSORT) statement. Second, to provide a reliable result for puerarin injection, more RCTs with multicenter, higher methodological quality, larger sample size, and longer treatment duration were still demanded.

CONCLUSION
This meta-analysis suggested that puerarin injection as adjunctive therapy was superior to Western medicine alone in treating UAP. However, due to the low-quality RCTs, more strictly designed RCTs with higher methodological quality, larger sample size, and longer treatment duration are still recommended to provide reliable evidence for puerarin injection.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS
HS: design, conception, searching the literature, extracting data, evaluating quality, performing statistical analysis, interpreting data, and drafting and revising the manuscript. YH: searching the literature, extracting data, evaluating quality, performing statistical analysis, interpreting data, and drafting the manuscript. DX: searching the literature, extracting data, evaluating quality, interpreting data, and drafting the manuscript. SH: design, conception, performing statistical analysis, interpreting data, and drafting and revising the manuscript. RT: design, conception, and revising manuscript. All authors approved the final version of the manuscript.

FUNDING
This work was supported by the National Key Research and Development Program of China (2020YFC2005500), the Key Research and Development Program of Science and Technology Department of Sichuan Province (2019YFS0514), the China Postdoctoral Science Foundation (2021M690559), and the Young Talents Project of Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital (Grant: 2021QN07).

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.763567/full#supplementary-material
REFERENCES

1. Bernard R, Corday E, Eliasch H, Gonin A, Hiait R, Nikolaeva LF, et al. Nomenclature and criteria for diagnosis of ischemic heart disease, the joint international society and federation of cardiology/world health organization task force on standardization of clinical nomenclature. Circulation. (1979) 59:607–9. doi: 10.1161/01.CIR.59.3.607

2. Shao HK, Li MS, Chen FC, Chen LH, Jiang ZJ, Zhao LG. The efficacy of Danshen injection as adjunctive therapy in treating angina pectoris: a systematic review and meta-analysis. Heart Lung Circ. (2018) 27:433–42. doi: 10.1016/j.hlc.2017.10.016

3. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American heart association statistics committee and stroke statistics subcommittee. Circulation. (2007) 115:5–92. doi: 10.1161/CIRCULATIONAHA.106.179918

4. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cerneck B, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Circulation. (2011) 124:574–651. doi: 10.1161/CIR.0b013e31823a5596

5. Duan L, Xiong XJ, Hu JY, Liu YM, Wang J. Efficacy and safety of oral Panax notoginseng saponins for unstable angina patients: a meta-analysis and systematic review. Phytomedicine. (2018) 47:23–33. doi: 10.1016/j.phymed.2018.04.044

6. Yu DD, Liao X, Robinson N, Cui RZ, Zhao I, Zhao H. 12 kinds of Chinese medicine injections for acute cerebral infarction: protocol for a systematic review and network meta-analysis. Eur J Integr Med. (2019) 27:75–80. doi: 10.1016/j.eujim.2019.02.012

7. Maji AK, Pandit S, Banerji P, Banerjee D. Puerarin tuberculosis: a review on its phytochemical and therapeutic potential. Nat Prod Res. (2014) 28:2111–27. doi: 10.1080/14786419.2014.928291

8. Zhang Z, Lam TN, Zuo Z. Radix puerariae: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J Clin Pharmacol. (2013) 53:787–811. doi: 10.1177/0022049612479009

9. Song XP, Chen PP, Chai XS. Effects of puerarin on blood pressure and plasma renin activity in spontaneously hypertensive rats. Acta Pharmacol Sin. (1988) 9:55–8.

10. Wei SY, Chen Y, Xu XY. Progress on the pharmacological research of puerarin: a review. Chin J Nat Med. (2014) 12:407–14. doi: 10.1007/S1675-5364(14)00064-9

11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

12. Shao HK, Zhao LG, Chen FC, Zeng SB, Liu SQ, Li JI. Efficacy of ligustriodium injection as adjunctive therapy for angina pectoris: a systematic review and meta-analysis. Med Sci Monit. (2015) 21:3704–15. doi: 10.12659/MSM.895362

13. Shao HK, He X, Zhang LJ, Du S, Yi XQ, Cui XJ, et al. Efficacy of ligustriodium injection as adjunctive therapy in treating acute cerebral infarction: a systematic review and meta-analysis. Front Pharmacol. (2021) 12:761722. doi: 10.3389/fphar.2021.761722

14. Shao HK, Fang CY, Huang Y, Ye YL, Tong RS. Sodium tanshinone IIA sulfinate injection as adjunctive therapy for the treatment of heart failure: a systematic review and meta-analysis. Phytomedicine. (2022) 95:153879. doi: 10.1016/j.phymed.2021.153879

15. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. Circulation. (2000) 102:1193–209. doi: 10.1161/01.CIR.102.10.1193

16. Cardiology CSO. Recommendations for the diagnosis and treatment of unstable angina pectoris. Chin J Cardiol. (2000) 28:409–12.
39. Zhang GQ, Hao XM, Dai DZ, Fu Y, Zhou PA, Wu CH. Puerarin blocks Na\(^+\) current in rat ventricular myocytes. *Acta Pharmacol Sin.* (2003) 24:1212–6.

40. He H, Shi M, Yang J, Zeng X, Qiao H, Wu L, et al. The correlation between angiogenesis and abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure, and improvement by puerarin. *Phytother Res.* (2008) 22:948–56. doi: 10.1002/ptr.2437

41. Tian F, Xu LH, Zhao W, Tian LJ, Ji XL. The optimal therapeutic timing and mechanism of puerarin treatment of spinal cord ischemia-reperfusion injury in rats. *J Ethnopharmacol.* (2011) 134:892–6. doi: 10.1016/j.jep.2011.01.055

42. Liu S, Zhang C, Shi Q, Li G, Song M, Gao Y, et al. Puerarin blocks the signaling transmission mediated by P2X3 in SG and DRG to relieve myocardial ischemic damage. *Brain Res Bull.* (2014) 101:57–63, doi: 10.1016/j.brainresbull.2014.01.001

43. Chen G, Pan SQ, Shen C, Pan SF, Zhang XM, He QY. Puerarin inhibits angiotensin II-induced cardiac hypertrophy via the redox-sensitive ERK1/2, p38 and NF-κB pathways. *Acta Pharmacol Sin.* (2014) 35:463–75, doi: 10.1038/aps.2013.185

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Shao, Huang, Xu, Huang and Tong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.